Cord blood units (CBUs) for transplantation should be free of communicable disease and must contain a specific amount of total nucleated cells and CD34 + cells. Although posttransplantation cytomegalovirus (CMV) infections are from latent infection in patients, ensuring CMV-free CBUs by performing CMV-specific IgM and nucleic acid amplification testing (NAT) is one of the mandatory procedures for the safety of CBUs. However, the exclusion policies (based on these test results) vary among nations and institutions. We tested 28,000 processed 
INTRODUCTION
Umbilical cord blood units (CBUs) for transplantation must be tested to ensure that they are free of transmissible infectious disease, to ensure that they contain the appropriate amount of total nucleated cells (TNCs), and to identify their human leukocyte antigen (HLA) status (4). On the basis of these test results, CBUs can then be selected for transplantation according to their HLA status and anticipated potency, which is represented by their TNC count and number of CD34 + cells (17) . In South Korea, public cord blood banks (pCBBs) store CBUs with a TNC count of 7 × 10 8 (12, 16, 22) , and a centralized Korean Network for Organ Sharing (KONOS) website (http://is.cdc.go.kr) has been developed to list characteristics of CBUs, including CD34 + cell counts, TNC count, sex of the baby, ABO and Rh blood groups, and HLA status. Therefore, transplantation physicians can use this database to identify CBUs that are appropriate for their patient.
To ensure patient safety, pCBBs perform testing for surface antigen of hepatitis B virus and antibodies to the human immunodeficiency virus (HIV), hepatitis C virus, human T-lymphotropic virus, syphilis, and cytomegalovirus (CMV) in both the maternal and cord blood plasma in South Korea (12, 16, 22) . CBUs with positive CMV IgM results in cord blood plasma could only be transferred to the inventory after confirming that the cord blood leukocytes tested negative for CMV using a CMV nucleic acid amplification test (NAT). CBUs with positive CMV IgM in the mother's plasma should be excluded without performing CMV NAT. In Western countries, several endemic diseases are also included in the routine tests for managing 64 SHIN ET AL.
CBUs, and the CMV NAT is performed at the time when the CBU is administered (1). The standard operating procedures of ALLCORD (Seoul Metropolitan Government Public Cord Blood Bank, Seoul, South Korea) also stipulate that the CMV NAT should be performed as a verification test before the CBU is issued, although no governmental regulatory bodies currently require CMV NAT for CBUs with negative CMV IgM results.
In the transplantation setting, CMV reactivation has been reported to affect treatment outcomes, resulting in morbidity and low survival rates, although it does not appear to affect graft outcomes (2). Although the posttransplantation CMV infection rate is higher for CBUs compared to alternative hematopoietic stem cell sources, the infection rate is comparable for donor-negative and recipient-positive procedures in the alternative transplantation setting (11). Therefore, it is important to confirm that CBUs are free from CMV and to test the mother's blood for anti-CMV IgM when screening for acute infection. Acute maternal infection increases the likelihood of congenital infection (10) and CMV DNAemia in the cord blood. However, testing the mother's blood for CMV IgM can be challenging, given the frequency of false-positive and false-negative test results (14, 19) . Furthermore, CMV acute infection only persists for 4-6 months, which may result in it being overlooked during the first trimester, and latent infection or reinfection is not frequently associated with positive IgM findings (6, 19) . Nevertheless, maternal CMV IgM testing is currently used to determine whether CBUs should be included in the pCBB inventory. In addition, CMV IgM-positive cord blood is subsequently subjected to CMV NAT, and only CBU with positive CMV NAT findings is excluded from the pCBB inventory (12, 16) . Because of some error, the KONOS database program does not import information of CBUs, which show CMV IgM positivity in the cord blood plasma and CMV NAT negativity in the cord blood leukocytes. Thus, such CBUs that conform to the Act on Cord Blood Management and Research (Cord Blood Act) (12) are neither searchable nor usable in the registry.
Recently, CBUs from IgM-positive mothers have been reported to have lower CD34
+ counts compared to CBUs from IgM-negative mothers (6) . Since this study included all donated cord blood without considering possible conforming units for inventory, the present study focused on units that passed the initial screening and reached the processing step. The study was designed to evaluate the association between CD34 + cell counts and maternal and cord blood CMV IgM status. This study would suggest robust principles for managing cord blood bank inventories. May 11, 2006, and June 24, 2014, 49,730 CBUs were donated to ALLCORD. All mothers signed a document stating that the donation was voluntary; they agreed that the donated cord blood could be processed for allogeneic transplantation therapy and that units not suited for transplantation could be used for research. The initial screening criteria to select CBUs for subsequent processing were as follows: informed consent from the mother, free of medical illness, no perinatal issues in either the baby or the mother, and a TNC number of ³8 × 10 8 (8, 16, 22) . On the basis of this screening, only 55% (28,000/49,730) of the donated CBUs were selected for processing. The processing procedure includes volume reduction and isolation of nucleated white blood cells to make CBUs, with simultaneous potency and safety tests using the retained sample. During the procedure, some CBUs cannot be cryopreserved because of damage to the bags, positive test findings for transmissible diseases in the maternal or cord blood plasma, and the absence of maternal blood for testing within 7 days of delivery, etc. Furthermore, exclusion from the pCBB inventory can occur after the cryopreservation stage if the baby's health is found to be poor due to a condition that would contraindicate transplantation.
MATERIALS AND METHODS

Between
The institutional review board (IRB) of Seoul's National University Boramae Hospital approved this study. All collection and processing of the CBUs were performed according to standard operating procedures (SOPs), as previously described (8).
Complete Blood and CD34 + Counts
The numbers of white blood cells (including neutrophils, lymphocytes, monocytes, eosinophils, and basophils), nucleated red blood cells, and platelets, as well as hemoglobin levels, were measured using the XE-2100 automated cell counter (Sysmex, Kobe, Japan). After CBU processing, the retained samples were used for counting the CD34 + cells. The CD34 + cell enumeration was performed using a commercially available kit (No. IM3630; BD Biosciences, San Jose, CA, USA) based on the singleplatform International Society of Hematotherapy and Graft Engineering method (8). The results were expressed as cells/µl, and the total CD34 + cell count per CBU was calculated by multiplying the number of CD34 + cells by 20 (expressed as cells/unit) (the final volume is 25 ml, including 5 ml of a cryopreservant).
CMV Testing
The mothers' plasma and cord blood plasma were used for CMV IgM and or IgG testing, which was performed using the ARCHITECT CMV IgM assay and/or CMV IgG (Abbott Laboratories, Abbott Park, IL, USA), as previously described (7). To detect CMV DNA, we used the CMV Early Complete Kit (NEK015-02 and NEK015-05; Nanogen Advanced Diagnostics S.p.A., Buttigliera Alta, Italy) according to the manufacturer's instructions. After extracting DNA from the concentrated reference sample, nested polymerase chain reaction (PCR) was used to detect the CMV major immediate early antigen gene (HCMVUL123), with the human b globin gene serving as the internal control for inhibition. The limits of detection of 50% positivity were 1.2 gEq/reaction (95% confidence interval: 0.9-1.7 gEq/reaction) and 2.6 gEq/reaction (95% confidence interval: 2.0-3.5 gEq/reaction) for cellular samples and noncellular samples, respectively.
Statistical Analysis
Prior to analyses, exploratory data analyses were performed to identify and remove extreme outlier values. All data were expressed as median and interquartile range (IQR) for continuous variables or as a frequency and proportion for categorical variables. Intergroup comparisons of continuous variables were performed using the Mann-Whitney U test, whereas the Pearson's chi-square test or Fisher's exact test was used for categorical variables. Spearman's rank correlation analysis was applied to examine the relationship between two continuous variables. Additionally, a multivariable linear regression model was conducted to assess which parameters were related with the concentrations of log-transformed CD34 + cells. Values of p < 0.05 were considered statistically significant. All statistical analyses were performed using R software (version 3.1.2, http://www.r-project.org).
RESULTS
CD34 + Cell Counts According to the Maternal CMV IgM Status
A total of 25,293 maternal plasma samples from the 28,000 processed CBUs were tested for CMV IgM, and the prevalence of CMV IgM in the mothers' plasma was 1.7% (441/25,293) ( (Fig. 1 ). There were no other significant differences among cord blood parameters with the maternal CMV IgM status, except the platelet counts, which were significantly higher among IgM-negative mothers (p = 0.0022). The CD34 + cell count of CBUs of CMV IgM positivity showed no difference from those of CMV IgM negativity in the cord blood plasma.
Cord Blood-Related Characteristics Affecting CD34 + Cell Concentration
Not only the maternal CMV IgM status but also the babies' sex, body weight, the gestational age, and maternal age affect log-transformed CD34 + cell concentration ( Table 2) . Babies of female sex, heavy birth weight, and short gestational age as well as older maternal age showed a higher number of CD34 + cells.
Comparing the CMV IgM Findings From Maternal Plasma and Cord Blood Plasma
For comparison, we started with the 25,260 CBUs, which have CMV IgM results from the maternal plasma and cord blood plasma. The overall prevalence of maternal CMV IgM positivity was 1.7% (441/25,260) , and the overall prevalence of cord blood CMV IgM positivity was 0.4% (112/25,260) . However, when we compared the test results for the paired samples, the maternal CMV IgM status did not appear to fully reflect that of the cord blood (chi-square p < 0.001, k value = 0.22) ( Table 3 ). All the maternal CMV IgM + samples were positive for CMV IgG.
Sensitivity and Specificity of the CMV IgM Status for Predicting Cord Blood CMV DNAemia
Among the 517 concentrated CBUs that tested positive for CMV IgM (maternal or cord blood plasma), only 0.58% CBUs (3/517) had positive CMV NAT findings. Neither the maternal CMV IgM positivity nor the cord blood CMV IgM positivity had sufficient sensitivity or specificity to predict cord blood CMV DNAemia (Table 4) .
Maternal CMV IgG Status
In the beginning, we did both CMV IgG and CMV IgM tests on maternal blood. Since nearly all the tested mothers were positive for CMV IgG, we changed our policy not to test CMV IgG for mothers after July 2011. The total number of CMV IgG tests done was 18,818. The CMV IgG seroprevalence among pregnant women was 98.1% (18,459/18,818) , and the results according to the mothers' ages are listed in Table 5 .
DISCUSSION
The multivariate linear regression results between some cord blood characteristics and CD34 + cells in this report robustly support our previous report with 11,098 CBUs (8). The CD34 + cell concentration was positively correlated with female sex, heavy birth weight, and short gestational period ( Table 2 ). The maternal age is the newly added parameter that positively affects CD34 + cell concentration. When managing pCBBs, it is equally important to exclude CBUs that may contain transmissible disease and to store as many appropriate CBUs as possible. However, after infection, CMV is chronically present in the body, irrespective of whether active disease is observed. Furthermore, CMV resides in CD34 + bone marrow cells (3, 21) and is known to cause myelosuppression (13). Interestingly, our findings regarding the lower number of CD34 + cells in CBUs from CMV IgM-positive mothers are in agreement with previously reported findings (6) .
Therefore, the CMV IgM test is important in determining the safety and potency of CBUs, as the CD34 + cell count is the second most important factor (following In our experience, 65.5% (18,326/28,000) of the CBUs passed the initial safety screening. They were "the candidates" in the inventory irrespective of CMV-related tests (Table 6 ). Only 1.6% (307/18,326) of the candidates were subsequently excluded from the inventory because of the maternal CMV IgM status (12). This exclusion would create additional storage space for better CBUs such as those with higher CD34 + cell counts, which are expected to provide good clinical outcomes.
If we exclude CBUs with CMV IgM positivity in cord blood plasma and CMV IgM negativity in the mother's plasma from the inventory irrespective of CMV NAT in cord blood leukocytes, 0.3% (54/18,326) of CBUs were excluded, which minimally affects the inventory pool in South Korea. The policy that excludes CBUs only after CMV NAT test in cord blood leukocytes could not be justified because of low sensitivity and specificity (Table 4) . Thus, excluding CBUs with positive CMV IgM in the cord blood would be a better option in terms of ensuring the quality of CBUs. Consequently, regulations in the Cord Blood Act should be revised.
In this study, among the CBUs with a positive maternal or cord blood plasma CMV IgM status, positive CMV NAT findings in cord blood leukocytes were only observed in three cases (0.58%, 3/517) ( Table 5) . Among these three cases, only two (67%) were positive for CMV IgM in the maternal plasma, whereas the other case was positive for IgM in the cord blood plasma. None of the three babies exhibited symptoms until the final 6-month follow-up. Some researchers use CMV NAT in the cord blood for the second screening step for CMV in inventory (15). On the basis of our data, CMV NAT in cord blood leukocytes cannot substitute CMV serology of mother's plasma in the second screening step of CBU storage because of low sensitivity and specificity. CMV serology testing is the cheaper option, as the cost of CMV PCR is 1.6-fold higher than that of CMV IgM testing under the Korean health insurance coverage.
CMV NAT in cord blood leukocytes may still be appropriate as confirmatory testing when CBUs are issued for transplantation. Theiler et al. reported that two CBUs with positive CMV NAT findings came from mothers who were negative for CMV IgM (20). CMV DNAemia can be detected in CBUs from IgM-negative mothers; performing CMV NAT immediately before a CBU's release can provide evidence (per the European directive) that the CBU is free from CMV (4).
We have issued 192 CBUs for transplantation before December 2014, and none of these CBUs have exhibited positive CMV NAT findings. This may be explained by the fact that CMV IgG seroconversion only during pregnancy has been reported to increase the risk of congenital CMV infection by threefold compared to seroconversion before conception (3% vs. 1%) (5). Therefore, pregnant women with high seroprevalence and low primary infection during pregnancy have a lower risk of congenital CMV infection and a lower risk of CMV DNAemia in their cord blood. In our institution, before the Cord Blood Act was instituted in 2011 (12,16), both CMV IgM and IgG testings were performed for both the maternal and cord blood plasma samples. When we analyzed that data, the CMV IgG seroprevalence among pregnant women was 98.1% (18,459/18,818) , and the results according to the mothers' age are listed in Table 6 . This seroprevalence was slightly higher than the reported seroprevalence of 91% in a Japanese study (18) and 93% in an American study (20) . In terms of the primary infection, only 1.7% of our donors were positive for CMV IgM, which is similar to the reported rates of 2% (10/486) in the US (20) and South Korea (18), and lower than the reported rate of 5% (43/857) in Mexico (6, 15, 18) . Therefore, a high seroprevalence and low primary infection in women of childbearing age may provide more suitable CBUs for storage (i.e., those negative for CMV) compared to CBUs from women with a low seroprevalence and acute primary infection. Additional experience is needed to determine the usefulness of CMV NAT at CBU release, particularly in the Korean population, where there is high maternal seroprevalence and a relatively low primary infection (18).
Unfortunately, we did not perform CMV IgG avidity testing to discriminate between recent and old infections (9,18). However, given the reported high avidity of CMV antibodies in the Korean population (18), a recent study has questioned the utility of the CMV IgM avidity test (9), which may reduce the usefulness of this test in the Korean population.
In conclusion, our data indicated that it is appropriate to use CMV serology and to exclude CBUs with CMV IgM positivity in cord blood plasma as well as CBUs with CMV IgM positivity in maternal plasma in South Korea, where women of childbearing age are highly immunized with CMV and sensitive enough CMV serology tests can be widely used. However, when releasing stored CBUs, using the CMV NAT to screen for CMV DNAemia may be appropriate until sufficient experience has been accumulated regarding the use of CBUs from mothers with a high CMV seroprevalence and low primary infection. The numbers of nonconforming conditions are presented with the V mark: V for 1, VV for 2, VVV for 3, and VVVV for 4. A, low total nucleated cells; B, microorganism growth; C, unable to separate the nucleated cell layer; D, other medical history of baby's relatives; E, low CD34 count; F, positive anti-hepatitis C virus (HCV) antibody in cord blood; G, positive syphilis test in cord blood; H, positive hepatitis B surface antigen (HBsAg) in cord blood; I, low cell viability; J, time elapsed from collection >36 h; K, usage for internal quality control; L, no maternal blood for testing; M, no informed consent for donation; N, used for transplantation; O, unacceptable maternal medical history; P, positive HBsAg in maternal sample; Q, positive anti-HCV antibody in maternal sample; R, alanine transaminase >65 U/L in the maternal sample; S, positive syphilis test in the maternal sample; T, positive anti-human T-lymphotropic virus antibody in the maternal sample. 
